LABCORP HOLDINGS INC. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2021-02-12

Reporting Person: Kirchgraber Paul R (CEO, Covance Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-12	Common Stock	M	264	—	Acquired	8335	Direct
2021-02-12	Common Stock	F	87	$238.26	Disposed	8248	Direct
2021-02-12	Common Stock	M	317	—	Acquired	8565	Direct
2021-02-12	Common Stock	F	93	$238.26	Disposed	8472	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-12	Restricted Stock Unit	$	M	264	Disposed		Common Stock (264)	Direct
2021-02-12	Restricted Stock Unit	$	M	317	Disposed		Common Stock (317)	Direct

Footnotes

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2: Stock withholding to satisfy tax withholding obligations.

F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested.

F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

F5: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020.